Plasminogen activation pathway

The **plasminogen activation pathway** comprises a tightly regulated system that converts plasminogen, primarily synthesized in the liver, into the enzyme **plasmin** via the action of tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA)[3][6][7][1]. Plasmin is responsible for degrading fibrin in blood clots (fibrinolysis), facilitating wound healing, and supporting tissue remodeling. **tPA** functions mainly in blood vessels on fibrin clots, while **uPA** is localized to cell surfaces and involved in extracellular matrix breakdown during cell migration and metastasis[3][6][1]. Regulatory proteins such as **PAI-1** and **PAI-2** inhibit the activity of the activators—dysregulation can lead to excessive bleeding or thrombosis. Besides thrombosis and stroke, the pathway plays significant roles in cancer (tumor invasion and metastasis), inflammation, and is sometimes hijacked by bacterial pathogens (e.g., streptokinase uses this pathway for host invasion)[5]. Therapeutic interventions targeting components of this pathway include recombinant tPA (alteplase, reteplase, tenecteplase) for ischemic stroke, and plasminogen replacement for inherited deficiency[8][7]. In summary, "Plasminogen activation pathway" is a biologically and clinically critical pathway, but as written, does not identify a single molecular therapeutic target and is better classified as a signaling or enzymatic cascade rather than as a receptor, enzyme, or transporter. Individual constituents such as tPA, uPA, and plasminogen should be specified for structured target information.

Other names

Fibrinolytic systemPlasminogen activator systemPA system

Enzymatic activation of plasminogen to plasmin by tPA or uPA, resulting in fibrin cleavage and clot dissolution Inhibition of plasminogen activation via serpins such as PAI-1 or synthetic inhibitors Bacterial proteins (streptokinase, staphylokinase) act as non-human plasminogen activators